Literature DB >> 2300106

Trial of different intensities of anticoagulation in patients with prosthetic heart valves.

J N Saour1, J O Sieck, L A Mamo, A S Gallus.   

Abstract

We compared the efficacy and complications of anticoagulation with warfarin in 258 patients with prosthetic heart valves treated with regimens of "moderate intensity" (prothrombin-time ratio, 1.5; international normalized ratio, 2.65) or "high intensity" (prothrombin-time ratio, 2.5; international normalized ratio, 9) in a prospective, randomized study. The two patient groups were followed up for 421 patient-years and 436 patient-years, respectively. Eleven patients were lost to follow-up. Thromboembolism occurred with similar frequency in the two groups (4.0 and 3.7 episodes per 100 patient-years, respectively), but there was a total of 6.2 bleeding episodes per 100 patient-years in the moderate-intensity group, as compared with 12.1 episodes in the high-intensity group (P less than 0.002). There were 5.2 episodes of minor bleeding per 100 patient-years in the moderate-intensity group, as compared with 10.1 episodes in the high-intensity group (P less than 0.01). Major bleeding was also more common in the high-intensity group (2.1 episodes per 100 patient-years--including the only two fatal hemorrhages--as compared with 0.95 episode in the moderate-intensity group), but the difference was not statistically significant. We conclude that a moderate anticoagulant effect (prothrombin-time ratio, about 1.5) in patients with a mechanical prosthetic heart valve offers protection equivalent to that of more intensive therapy, but at a significantly lower risk.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2300106     DOI: 10.1056/NEJM199002153220703

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  39 in total

1.  Oral anticoagulation and risk of death: a medical record linkage study.

Authors:  Anders Odén; Martin Fahlén
Journal:  BMJ       Date:  2002-11-09

2.  Deep Vein Thrombosis.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-06

3.  Survey of oral anticoagulant treatment in children.

Authors:  D I Evans; M Rowlands; L Poller
Journal:  J Clin Pathol       Date:  1992-08       Impact factor: 3.411

Review 4.  Non-rheumatic atrial fibrillation: warfarin or aspirin for all?

Authors:  J Nolan; P Bloomfield
Journal:  Br Heart J       Date:  1992-12

5.  Low-Dose Vitamin K Therapy in Excessively Anticoagulated Patients: A Dose-Finding Study.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 6.  Therapeutic ranges for oral anticoagulation in different thromboembolic disorders.

Authors:  L Poller
Journal:  Ann Hematol       Date:  1992-02       Impact factor: 3.673

7.  Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Richard P Whitlock; Jack C Sun; Stephen E Fremes; Fraser D Rubens; Kevin H Teoh
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 8.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

9.  Achieved anticoagulation vs prosthesis selection for mitral mechanical valve replacement: a population-based outcome study.

Authors:  Thierry Le Tourneau; Vanessa Lim; Jocelyn Inamo; Fletcher A Miller; Douglas W Mahoney; Hartzell V Schaff; Maurice Enriquez-Sarano
Journal:  Chest       Date:  2009-05-29       Impact factor: 9.410

Review 10.  Drug treatment associated with heart valve replacement.

Authors:  D S Coulshed; M A Fitzpatrick; C H Lee
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.